Blood markers to help diagnose acute mesenteric ischemia

Evaluation of the Discriminative Abilities of Biomarkers for the Diagnosis of Acute Mesenteric Ischemia Compared With Another Similar Clinical Presentation: a Pilot Study

We will test whether measuring adenosine deaminase in blood helps doctors quickly diagnose acute mesenteric ischemia in adults who come to hospital with severe unexplained abdominal pain.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 130 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Assistance Publique Hopitaux De Marseille (Academic / other)
• Locations: 1 site (Marseille)
• Trial ID: NCT06869564 on ClinicalTrials.gov

What this trial studies

This pilot interventional study collects blood samples from adults presenting with severe unexplained abdominal pain who are undergoing contrast-enhanced abdominopelvic CT to rule out acute mesenteric ischemia (AMI). Investigators measure soluble plasma adenosine deaminase activity and lymphocyte-bound adenosine deaminase, then compare biomarker levels between patients with CT-confirmed AMI and those with similar clinical presentations without AMI. The primary goal is to determine the discriminatory capacity (sensitivity and specificity) of these ADA measurements for earlier diagnosis, since standard markers like lactate often rise late. The study enrolls adults including pregnant and breastfeeding patients and is conducted at Timone Hospital in Marseille according to French consent regulations.

Who should consider this trial

Good fit: Adults aged 18 or older who present with severe unexplained abdominal pain and have an indication for a contrast abdominopelvic CT to rule out suspected acute mesenteric ischemia, are affiliated with the French social security system, and can give written non-opposition are ideal candidates.

Not a fit: Patients with acute myocardial ischemia (which can raise adenosine deaminase), those unable to read French or give consent, and legally protected persons excluded under French law are unlikely to benefit or to be eligible.

Why it matters

Potential benefit: If successful, this biomarker could help doctors diagnose AMI earlier, potentially enabling timelier revascularization and reducing mortality and bowel loss.

How similar studies have performed: Adenosine deaminase has been reported in myocardial ischemia, but using ADA as a biomarker specifically for acute mesenteric ischemia is novel and unproven in prior studies.

Eligibility criteria

Inclusion Criteria:

* Male or female, 18 years of age or older
* with an indication (hyperintense abdominal pain with no obvious diagnosis other than acute mesenteric ischemia) for an injected abdominopelvic scan for hyperintense abdominal pain suspected of acute mesenteric ischemia
* Including pregnant or breast-feeding women, as this is a risk factor for AMI in young subjects
* Affiliated with the French social security system
* Able to express non-opposition in writing

Exclusion Criteria:

* Presenting acute myocardial ischemia, to avoid biasing the levels of the biomarkers studied (increased in this clinical situation)
* Patient in a period of exclusion from another research protocol at the time the non-opposition is signed,
* Person protected by articles L1121-6 and L1121-8 of the French Public Health Code (deprived of liberty by court order, socially vulnerable, adult incapable or unable to express non-opposition).
* Persons who are unable to read and understand the French language sufficiently to give their consent to participate in research.

Where this trial is running

Marseille

• Timone hospital — Marseille, France (Recruiting)

Study contacts

• Study coordinator: Diane Mège

Conditions Acute Mesenteric Ischemia